AKB-9778: Phase II started

Aerpio began a double-blind, placebo-controlled, U.S. Phase II trial to compare subcutaneous 15 mg AKB-9778 twice daily with and without 0.3 mg monthly intravitreal injections of Lucentis ranibizumab...